La Jolla Pharma, Abbott deal

The companies will develop and market LJPC’s LJP 394 lupus

Read the full 100 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE